Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Advaxis, Sorrento deal

    Advaxis Inc. (NASDAQ:ADXS), Princeton, N.J. Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Business: Cancer The companies partnered to evaluate Advaxis Listeria monocytogenes Listeriolysin O (Lm-LLO) cancer…

    Published on 7/20/2015
  • Alexza, Ferrer deal

    Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Mountain View, Calif. Grupo Ferrer Internacional S.A., Barcelona, Spain Business: Neurology The companies added the Middle East and North Africa region, Korea, the Philippines …

    Published on 7/20/2015
  • amp biosimilars deal

    amp biosimilars AG, Hamburg, Germany Business: Cancer, Biosimilars amp granted an undisclosed Chinese pharmaceutical company exclusive, Chinese rights to ABY-018. The humanized mAb is a biosimilar of an undisclosed …

    Published on 7/20/2015
  • Apogenix, Canbridge deal

    Apogenix GmbH, Heidelberg, Germany Canbridge Life Sciences Ltd., Beijing, China Business: Cancer Apogenix granted Canbridge Life Sciences exclusive rights to develop and commercialize APG101 in China, including Macao …

    Published on 7/20/2015
  • Bayer, Panasonic Healthcare Holdings deal

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Panasonic Healthcare Holdings Co. Ltd., Tokyo, Japan Business: Endocrine/Metabolic Panasonic Healthcare Holdings will acquire Bayers Bayer Diabetes Care arm for EUR1 billion ($…

    Published on 7/20/2015
  • Benitec, ReNeuron deal

    Benitec Biopharma Ltd. (ASX:BLT), Sydney, Australia ReNeuron Group plc (LSE:RENE), Guildford, U.K. Business: Cancer, Gene/Cell therapy Benitec and ReNeuron extended for one year an October 2014 deal to test the …

    Published on 7/20/2015
  • biOasis, National Research Council Canada, Universite de Sherbrooke deal

    biOasis Technologies Inc. (TSX-V:BTI;OTCQX:BIOAF), Vancouver, B.C. National Research Council Canada, Ottawa, Ontario Universite de Sherbrooke, Sherbrooke, Quebec Business: Neurology biOasis partnered with the National …

    Published on 7/20/2015
  • BioCryst, CSL deal

    BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C. CSL Ltd. (ASX:CSL), Melbourne, Australia Business: Infectious BioCryst granted CSLs bioCSL subsidiary exclusive, worldwide rights, excluding Japan, Korea, Taiwan…

    Published on 7/20/2015
  • Celsis, Charles River deal

    Celsis International Ltd., London, U.K. Charles River Laboratories International Inc. (NYSE:CRL), Wilmington, Mass. Business: Supply/Service, ADMET Charles River will acquire supply/service company Celsis for $212 …

    Published on 7/20/2015
  • Fast-track diagnostics, Biocartis deal

    Fast-track diagnostics Ltd., Sliema, Malta Biocartis Group N.V. (Euronext:BCART), Mechelen, Belgium Business: Diagnostic The companies partnered to develop multiplex infectious disease tests that will run on Biocartis …

    Published on 7/20/2015
  • Francis Crick Institute, GlaxoSmithKline deal

    Francis Crick Institute, London, U.K. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Infectious, Cancer The partners will conduct pre-translational research under a deal combining the institutes disease …

    Published on 7/20/2015
  • InDex, Almirall deal

    InDex Pharmaceuticals AB, Stockholm, Sweden Almirall S.A. (Madrid:ALM), Barcelona, Spain Business: Autoimmune The companies terminated a 2014 deal granting Almirall European rights to develop and commercialize …

    Published on 7/20/2015
  • Inhibrx, Five Prime deal

    Inhibrx LLC, La Jolla, Calif. Five Prime Therapeutics Inc. (NASDAQ:FPRX), South San Francisco, Calif. Business: Cancer Inhibrx granted Five Prime exclusive, worldwide rights to develop and commercialize Inhibrxs …

    Published on 7/20/2015
  • Inovio, GeneOne deal

    Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. GeneOne Life Science Inc. (KSE:011000), Seoul, South Korea Business: Infectious The companies will co-develop Inovios INO-4500 vaccine against Middle East …

    Published on 7/20/2015
  • Max Planck Society, Vaxxilon deal

    Max Planck Society, Munich, Germany Vaxxilon AG, Reinach, Switzerland Business: Infectious Max Planck and Actelion Ltd. (SIX:ATLN, Allschwil, Switzerland) launched Vaxxilon. The company has exclusive, worldwide rights …

    Published on 7/20/2015
  • Medical Futures, Tribute Pharmaceuticals deal

    Medical Futures Inc., Richmond Hill, Ontario Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF;TSX-V:TRX), Milton, Ontario Business: Neurology Tribute acquired Medical Futures for C$8.3 million ($6.7 million) in cash up …

    Published on 7/20/2015
  • NeuroVive, Sanofi deal

    NeuroVive Pharmaceutical AB (SSE:NVP;Pink:NEVPF), Lund, Sweden Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Cardiovascular NeuroVives NeuroVive Pharmaceutical Asia Inc. subsidiary granted Sanofi rights to …

    Published on 7/20/2015
  • Oncos, Targovax deal

    Oncos Therapeutics Ltd., Helsinki, Finland Targovax A/S, Lysaker, Norway Business: Cancer The companies completed their merger. Oncos received about 9.4 million new Targovax shares at NOK25 per share, or about NOK235.7 …

    Published on 7/20/2015
  • OncoSec, Massachusetts General Hospital deal

    OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Massachusetts General Hospital, Boston, Mass. Business: Infectious OncoSec and the hospital partnered to study immunologic mechanisms underlying the antitumor …

    Published on 7/20/2015
  • Receptos, Celgene deal

    Receptos Inc. (NASDAQ:RCPT), San Diego, Calif. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Autoimmune Celgene will acquire Receptos for $232 per share, or $7.3 billion based on 31.6 million shares outstanding on…

    Published on 7/20/2015
  • Roche, Halozyme deal

    Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Business: Pharmacogenetics Halozyme and Roches Ventana Medical Systems Inc. unit partnered to develop and …

    Published on 7/20/2015
  • University of Maryland, Biomecite Diagnostics deal

    University of Maryland, College Park, Md. Biomecite Diagnostics LLC, Baltimore, Md. Business: Diagnostic The university granted Biomecite an exclusive option to develop diagnostics to detect inflammatory bowel diseases …

    Published on 7/20/2015
  • University of Minnesota, Fate Therapeutics deal

    University of Minnesota, Minneapolis, Minn. Fate Therapeutics Inc. (NASDAQ:FATE), San Diego, Calif. Business: Cancer Fate partnered with the university to develop NK cell-based, off-the-shelf immunotherapies for cancer.…

    Published on 7/20/2015
  • University of Rochester, Vivione deal

    University of Rochester, Rochester, N.Y. Vivione Biosciences Inc. (TSX-V:VBI), Dallas, Texas Business: Infectious The university granted Vivione an option for exclusive, worldwide rights to neutrophilic integrin alpha(3…

    Published on 7/20/2015
  • Affibody, Biotest deal

    Affibody AB, Stockholm, Sweden Biotest AG (Xetra:BIO), Dreieich, Germany Business: Chemistry The companies will combine Affibodys Albumod technology, which improves the circulatory half-life of biopharmaceuticals, with …

    Published on 7/13/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993